Market Overview:

The global anti-venom market reached a value of US$ 1,023.40 Million in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1,544.40 Million by 2027, exhibiting a CAGR of 6.80% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Anti-venoms are purified antibodies used to stop snake venom from binding to tissues and causing severe allergic reactions, blood-clotting, muscle injury, or nervous system problems. They can prevent or reverse the snakebite envenoming effects, which help minimize mortality and morbidity. They are obtained from different animal species, such as snakes, funnel web spiders, stonefish, redback spiders, and box jellyfish, using different technologies. Presently, the type of anti-venom generally used depends on the history and examination of the patient and geographic, clinical, and pathologic factors.

Anti-Venom Market Trends:

The risk of snakebite envenoming is a public health hazard that people, especially in the rural areas, experience on a regular basis. It causes occupational injury among several agricultural workers and hunters, which represents one of the key factors driving the need for safe, effective, and affordable anti-venoms. In addition, open-plan housing and the practice of sleeping on the floor, common in tropical regions, can expose people to bites from nocturnal and highly venomous snakes and cause serious health problems. These health problems usually include kidney failure, severe paralysis that prevents breathing, bleeding disorders that can lead to fatal hemorrhage, and severe local tissue destruction that can cause permanent disability and result in limb amputation. This, in turn, is catalyzing the demand for anti-venoms across the globe. Apart from this, there is an introduction of snake venom detection kits with a rapid enzyme immunoassay for in vitro detection and immunological identification of snake venom in samples from bite sites, urine, plasma, blood, or other tissues and body fluids. This is anticipated to offer lucrative growth opportunities to industry players and drive the overall market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-venom market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on species, anti-venom type, mode of action and end user.

Breakup by Species:

• Snake
• Scorpion
• Spider
• Others
   

Breakup by Anti-venom Type:

• Polyvalent Anti-venom
• Monovalent Anti-venom
   

Breakup by Mode of Action:

• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others
   

Breakup by End User:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc. and Rare Disease Therapeutics Inc.

Report Coverage: